Weight loss and hair loss: The growing hair treatment market from GLP-1s

GLP-1 drug use has more than doubled since early 2024, with roughly 13% of U.S. adults now taking one, creating a growing hair-loss side-effect market. Circana says GLP-1 households spend about 30% more on beauty products, and brands like Redken, Nutrafol, and KeraFactor are reporting rising demand and product innovation tied to hair thinning concerns. The article points to a new consumer-health crossover opportunity rather than a broad negative impact, though it highlights an emerging side-effect risk for users.

Analysis

The incremental profit pool is not the weight-loss drug itself but the downstream “maintenance economy” that forms once users lock in and begin managing side effects. Hair thinning is especially attractive for beauty spend because it is visible, emotionally salient, and slow to resolve, which raises attachment rates for premium, repeat-purchase categories like scalp serums, supplements, and salon-adjacent treatments. That makes the category more resilient than typical discretionary beauty: users are not buying vanity, they are buying reassurance and control.

ULTA is the cleanest listed beneficiary because it aggregates discovery, trial, and replenishment across branded and indie products without needing to win the efficacy debate. The second-order effect is that basket size can rise even if traffic stays flat, as GLP-1 consumers over-index on multi-step routines and higher-ticket “clinical” SKUs. The bigger margin opportunity is private label and exclusive assortment, where ULTA can capture the halo without fully conceding pricing power to brands.

ACN is less obvious but has a credible angle: brands and retailers are now being forced to segment by medication status, symptom profile, and lifecycle stage, which increases demand for personalization, analytics, and omnichannel execution. The commercial winner will be whoever can convert vague demand into targeted repeat behavior; this is a data problem as much as a product problem. Conversely, brands that rely on generic hair-growth messaging risk ad inefficiency and promotional bleed as the market crowds.

The contrarian view is that the market may be overestimating the permanence of the revenue lift. Hair shedding is usually temporary and many users will self-resolve, so the spend spike may peak within 1-2 quarters of onset rather than compound indefinitely. The trade therefore should focus on companies that monetize trial and routine formation, not those dependent on a durable medicalized cure narrative.

Key Decisions for Investors

• Long ULTA over a 3-6 month horizon; thesis is basket expansion from GLP-1-driven hair-care demand and better margin capture from curated premium assortment. Risk/reward favors the long side if category spend persists beyond the initial scare cycle.
• Add ACN on weakness as an indirect beneficiary of beauty personalization and retail segmentation initiatives; 6-12 month view. The upside is tied to clients funding data/CRM/AI projects to target GLP-1 users more efficiently.
• Pair trade: long ULTA / short a lower-quality hair-care or broad discretionary retailer with weaker premium mix. Goal is to isolate the incremental spend toward the best assortment and execution platform.
• For event-driven traders, buy 3-6 month ULTA calls on any post-earnings pullback if management commentary confirms hair-care acceleration; avoid chasing after a strong move because the category is susceptible to normalization once users adapt.
• Stay cautious on pure-play hair-treatment names until there is evidence of repeat purchase and retention, not just search interest; the risk is a fast fade in demand once the temporary shedding window passes.